Be sure to attend Alina Sitaula's talk at #CGCAnnual2023 on OncoAlly hereditary cancer and solid tumor testing, happening today at 4:30pm.
When cancer's in your sights, #WeSeeMore. Learn more 👉 ow.ly/Kont50PyNBP
#hereditarycancer #cancertesting
2
271
Just 13 days following ACMG's published update, at Variantyx we've updated our ACMG secondary findings to version 3.2. Find out how by reading our news story: ow.ly/5HN650P3Zhf
#genechat #WeSeeMore
2
298
The list goes on ...
All in a single #wholegenome test.
Researchers, clinicians and advocates working towards a cure for #Duchenne muscular dystrophy (#DMD) are able to celebrate a significant milestone with the FDA's recent approval of #Elevidys - the first #genetherapy for Duchenne patients.
Variantyx #wholegenome testing identifies DMD variants missed by other technologies, providing a definitive genetic diagnosis. Download our latest case study to see why Seeing More with Variantyx testing makes a difference 👉 ow.ly/su2y50OZlKz #WeSeeMore #10000andCounting
The #ASCO2023 exhibit floor is open and it's impressive! Stop by and see us at booth # 13039 to learn why, with OncoAlly, "When cancer is in your sights, we see more".
3
131
We're all packed and excited to head to Chicago for #ASCO2023. Will we see you there? If so, be sure to stop by booth # 13039 June 3-5 to learn about our OncoAlly testing.
3
148
We're onsite today at the #FLAGC annual meeting - stop by to learn why Seeing More with Variantyx testing makes a difference
1
131
The exhibit floor is open in Baltimore! Stop by booth # 2126 to learn about #wholegenome testing for sensitive cases and high-risk pregnancies. At Variantyx, we see more so you know more. #ACOG2023 #WeSeeMore
3
117
The results are in! We're honored by our 9th place finish in Boston Business Journal's Fast 50 selection of Massachusetts' fastest growing private companies. Thanks #BBJFAST50 for a fun awards night!
When there's a sick child in the NICU or PICU, time is of the essence. This is why we're so excited to wrap up #WorldPICU2023 Awareness Week by announcing the launch of Genomic Unity® Lightning Genome Analysis - our ultra rapid #wholegenome test.
With a TAT of just 7 days, Lightning is the fastest way to reach a clear diagnostic outcome in acutely ill neonatal or pediatric patients. See the difference Lightning makes: variantyx.com/lightning #WPAW2023
1
66
It's not too late to sign up for tomorrow's webinar! Earn NSGC-recognized CEU credit while learning about what truly separates WGS from other NGS technologies.
Register at ow.ly/uM5V50OeY02
We're excited to share the recent publication of our study validating Oxford Nanopore Technologies long read sequencing for orthogonal confirmation of variants detected by short read-based clinical #wholegenome sequencing. @nanopore
Read the article at ow.ly/LZXr50OkFxN
It's another busy month for regional genetic counselor meetings. We're looking forward to being onsite in Illinois, Florida and southern California and hope to see you there!
1
102
Join us for a deep dive into what makes WGS different from other NGS technologies. In 30 minutes, you'll learn about the benefits & limitations of individual tests. Attendees will have the option to sign up for CEU credit recognized by NSGC.
Register at ow.ly/n8AB50O9Z6E
Happy DNA day! It's a particularly notable one as this year marks the 20th anniversary of the completion of the human genome project and the 75th anniversary of the discovery of DNA's double helix. #DNADay
Our team is onsite at #AANAM, sharing how Variantyx #wholegenome testing is making a difference for pediatric and adult neurology patients.
3
195
We're delighted to be part of Boston Business Journal's Fast 50, recognized as one of Massachusetts' fastest-growing private companies. We look forward to joining other honorees at the Fast 50 Awards May 17th.
3
160
The WHO turns 75 today! Join us in raising awareness about the importance of #HealthForAll, including those affected by #RareDisease.
#WHO75
2
126












